問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital

Division of Neurology

更新時間：2023-09-19

黃上芝
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃上芝

List

9Cases

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    錠劑

Participate Sites
9Sites

Not yet recruiting9Sites

2024-07-01 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-05-01 - 2027-06-24

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-04-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-12-01 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting3Sites

2021-12-01 - 2026-09-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2025-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated2Sites

2023-01-16 - 2025-08-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting13Sites

Terminated5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB